immatics is a biopharmaceutical company focused on developing therapeutics to treat cancer through targeted ‘tumor-associated HLA-binding peptides’ (TUMAPs). The technology platform of the company with its rational identification, selection and validation of TUMAPs extends its potential use to virtually every type of cancer.
IMA901, immatics’ most advanced product candidate, has completed a European multi-center Phase II clinical trial in kidney cancer (renal cell carcinoma) and moved into a Phase III trial in 2011. Patient recruitment has been completed in Q4 2012.
IMA910 successfully completed a Phase I/II study in colorectal cancer (CRC) in H1 2012.
IMA950 completed a 45 patient study in collaboration with Cancer Research UK in glioblastoma multiforme in early 2014.
IMA942 for gastric cancer has been partnered with Roche as part of a broader collaboration with immatics in November 2013 and will enter a large Phase I study in the near future.
immatics’ USP is to develop off the shelf products composed of tumor-associated HLA-binding peptides (TUMAPs) that are effective against oncologic diseases. The principle is to find and validate peptides that are specifically expressed on tumor cells. These peptides--as a cocktail of up to 12 different, yet specific peptides--are injected into the patients’ skin. There, they fit precisely into certain receptors of cells of the immune system that then trigger a specific immune response against the TUMAP targets on the surface of the tumor cells. Many cancer types could be addressable with this technology.